Drug intelligence / Profile preview

Jango-HPO-C1

Development stage: Preclinical
Lead developer: JangoBio
Modality: Cell Therapies
Administration: Implant

Overview

Jango-HPO-C1 is a canine-specific cell therapy candidate developed by JangoBio, utilizing their proprietary Hormone-Producing Organoid (HPO) technology. The therapy involves the implantation of bioengineered organoids designed to restore a natural, physiological balance of hormones, addressing the multi-hormonal decline associated with aging and hypogonadism. Unlike traditional single-hormone replacement therapies, Jango-HPO-C1 aims to provide a sustainable and comprehensive endocrine solution. It is currently in preclinical development (Proof of Concept stage) for the treatment of hypogonadism and the promotion of healthy aging in dogs.

Other names: canine HPOcanine Hormone-Producing Organoid

Beyond the preview

Go deeper on Jango-HPO-C1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jango-HPO-C1.

Explore the full profile